GlobeNewswire·Nov 9, 2026, 4:05 PM ET

Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

AVIR

Atea Pharmaceuticals reported positive topline results from the Phase 3 C-BEYOND trial in North America, where the BEM/RZR regimen demonstrated statistical non-inferiority to Epclusa (SOF/VEL) for treating chronic HCV, meeting both primary and secondary endpoints.
In the C-BEYOND modified intent-to-treat population, BEM/RZR achieved a 93.91% sustained virologic response rate at Week 24 compared to 94.75% for the comparator.
Topline results from the Phase 3 C-FORWARD trial in non-North American markets are anticipated in early 2027 to support a New Drug Application submission to the FDA targeted for mid-2027.
Atea advanced its Hepatitis E program by completing the single ascending dose portion of the Phase 1 trial for AT-587 and is currently conducting the multiple ascending dose portion with a proof-of-concept study anticipated in 2027.
The company secured a non-dilutive credit facility from Hercules Capital of up to $200 million, drawing down $65 million at closing on November 6, 2026.
Current cash, cash equivalents, investments, and the new credit facility are expected to fund operations into mid-2028, with potential to extend the runway to profitability upon successful commercial launch.
Third quarter 2026 research and development expenses decreased to $27.1 million from $38.3 million in the prior year period, driven by lower external spend on HCV Phase 3 clinical development.
General and administrative expenses decreased to $6.9 million in the third quarter of 2026 from $7.2 million in the same period of 2025, primarily due to lower stock-based compensation.
Total cash and investments stood at $191.2 million as of September 30, 2026, down from $301.8 million at the end of 2025.
Net loss for the three months ended September 30, 2026, was $32.2 million, or $0.40 per share, compared to a net loss of $42.0 million, or $0.53 per share, in the prior year period.

Company: Atea Pharmaceuticals, Inc.
Keywords: Nasdaq:AVIR, Atea Pharmaceuticals, Inc.